PharmaMarketing Summit Travels on May 11 -12, 2023 to an Exquisite Location: The Four Seasons Hotel Westlake Village, Westlake Village, CA, US

We are thrilled to announce that the PharmaMarketing Summit travels on 11 – 12 May 2023 to an exquisite location the Four Seasons Hotel Westlake Village, Westlake Village, CA, US.

The PharmaMarketing summit unites leading pharmaceutical marketing executives and innovative sponsors in an exclusive networking environment. The Summit’s content is aligned with key pharma marketing challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers.

The PharmaMarketing provides the opportunity to attendees to pre-schedule one-on-one physical business meetings with key leading and forward-thinking executives.

Delegates include:

  • CEO and Founder – Ascertain Biosciences
  • Head of Digital Innovation & Marketing Operations – Azurity Pharmaceuticalss
  • VP, Global Market Access – Bayer AG
  • Director of Marketing, HAE Franchise – CSL Behring
  • Director, Medical Science Liaison – Immunovant, Inc.
  • North America Brand Lead, Rare Disease Franchise – Kyowa Kirin
  • Vice President – Global Commercial Operations – Merck

To find more information you can visit https://events.marcusevans-events.com/pharmamarketing-may2023/ or contact directly Isidora Avraam at isidoraa@marcusevanscy.com. #MKTSummit

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.